Evolent Health Files 8-K on Operations & Financial Condition

Ticker: EVH · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1628908

Complexity: simple

Sentiment: neutral

Topics: financial-condition, regulation-fd, corporate-governance

TL;DR

**Evolent Health just dropped an 8-K with fresh financial deets, keep an eye out for specifics.**

AI Summary

Evolent Health, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition, as well as Regulation FD disclosure and financial statements. This filing, under SEC File Number 001-37415, indicates that the company is providing current information to the public. For investors, this matters because it signals transparency and provides updated financial insights, which can influence stock valuation and investment decisions.

Why It Matters

This filing provides updated financial information, which is crucial for investors to assess the company's current health and make informed decisions about buying, holding, or selling its stock.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial information and does not inherently present new risks, but rather provides data for risk assessment.

Analyst Insight

Investors should review the detailed financial statements and results of operations once they become available to understand the company's performance and future outlook, as this 8-K signals their imminent release.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of Evolent Health, Inc.'s 8-K filing on January 8, 2024?

The primary purpose of Evolent Health, Inc.'s 8-K filing on January 8, 2024, is to report on its 'Results of Operations and Financial Condition', 'Regulation FD Disclosure', and 'Financial Statements and Exhibits', as stated in the 'ITEM INFORMATION' section.

What is Evolent Health, Inc.'s trading symbol and on which exchange is it registered?

Evolent Health, Inc.'s trading symbol is EVH, and its Class A Common Stock is registered on the New York Stock Exchange, as indicated under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the state of incorporation for Evolent Health, Inc.?

Evolent Health, Inc. is incorporated in Delaware, as specified under 'State or other jurisdiction of incorporation or organization'.

What is the business address and phone number for Evolent Health, Inc. as listed in the filing?

The business address for Evolent Health, Inc. is 1812 N. Moore Street, Suite 1705, Arlington, Virginia, 22209, and its telephone number is (571) 389-6000, according to the filing's header information.

Does this 8-K filing indicate that Evolent Health, Inc. is an emerging growth company?

No, the filing indicates that Evolent Health, Inc. is NOT an emerging growth company, as the box 'Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act' is unchecked.

Filing Stats: 711 words · 3 min read · ~2 pages · Grade level 10.3 · Accepted 2024-01-08 17:00:04

Key Financial Figures

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition On January 9, 2024, Evolent Health, Inc. (the "Company") will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference. In connection with this presentation and investor meetings, the Company is reaffirming previously issued revenue and Adjusted EBITDA guidance for the three months and year ended December 31, 2023 and announces two new revenue contracts for its technology and services suite, including a new partner logo in the Southwest and the cross-sell of NIA services to a legacy Evolent client in the northeast. Because the Company's financial statements for the year ended December 31, 2023, have not been finalized or audited, these preliminary statements regarding the Company's estimated full-year revenue and Adjusted EBITDA are subject to change and the Company's actual results as of the end of this period may differ materially from these preliminary statements. Accordingly, you should not place undue reliance on these preliminary statements.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure The disclosure contained in Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference. A copy of the investor presentation materials for the Company's presentation at the 42nd Annual J.P. Morgan Healthcare Conference is furnished as Exhibit 99.1 and is incorporated herein by reference. The Company may use this updated corporate presentation in meetings with investors from time to time as well. The information furnished under Items 2.02 and 7.01 of this Report, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 99.1 Investor Presentation 104 The cover page from this Current Report on Form 8-K, formatted as Inline XBRL

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EVOLENT HEALTH, INC. By: /s/ Jonathan D. Weinberg Name: Jonathan D. Weinberg Title: General Counsel and Secretary Date: January 8, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing